Gilead Sciences (NASDAQ:GILD)

ThinkstockPhotos-475472230

Top Analyst Upgrades and Downgrades: Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital, Whiting Petroleum and More

Stocks had a rough Thursday and futures were indicated lower on Friday. Despite the drop, we have yet to see any serious selling pressure in a while and investors still ...
Read Full Story »
clinical trials

Gilead Results Trip Over Both the Top and Bottom Lines

Gilead Sciences Inc. (NASDAQ: GILD) reported first-quarter financial results after the markets closed on Thursday. The company had $3.03 in earnings per share (EPS) on $7.79 billion in revenue compared ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Prescription Drugs, Pills

The World’s 15 Top Selling Drugs

Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also help generate billions for drug manufacturers. Pharmaceutical companies generate an ...
Read Full Story »
investing

UBS Makes Major Changes to Equity Focus List for Q2

All the firms we cover on Wall Street have a list of their highest conviction stock ideas for institutional and high net worth clients, and with the second quarter underway, ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the March 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
graph

5 Biotechs With the Most Upside This Earnings Cycle

With earnings just around the corner, one key analyst is taking the opportunity to share its thoughts on select mid-cap and large-cap biotech companies. Despite a modest erosion to fundamentals and sector ...
Read Full Story »
gavel and cash money

How Ionis Pharma Beat a Biotech Giant

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system. The company announced that a jury in the U.S. ...
Read Full Story »
automatic inspection machine

Why One Analyst Sees Gilead Worth 66% More

Gilead Sciences Inc. (NASDAQ: GILD) has been touted by many analysts as being a great value stock with serious upside ahead. Gilead remains the top biotech stock that remains well ...
Read Full Story »
biotech word cloud

Short Sellers Back Off of Major Biotechs

The short interest data are out for the February 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
automatic inspection machine

Big Pharma Matchup: Valeant vs Gilead

While small cap biotech is a minefield of volatility, the mega caps can be just as fickle, and indeed have been lately. The fortunes of double-digit or even triple-digit multibillion ...
Read Full Story »
biotech word cloud

Why Citi Sees Huge Upside in 4 Top Biotechs Now

If there was one sector inside of a broader health care theme that performed well through much of 2015, it was biotech. That was then, and this is now. A ...
Read Full Story »
graph

Short Interest Rises Across the Board in Major Biotechs

The short interest data are out for the February 12 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
buy button

The 18 Companies That Will Buy Back the Most Stock in 2016

When corporations are profitable and established, they tend to return capital to shareholders. This can be achieved via stock buybacks to shrink the float and to support the stock, or ...
Read Full Story »
automatic inspection machine

6 Biotech and Pharma Stocks Analysts Want You to Buy Now

The end of 2015 and the start of 2016 have been hard on biotech, and in some cases have been hard for Big Pharma. It turns out that there is ...
Read Full Story »